The Lancet Regional Health. Europe (Mar 2021)
Myocardial Infarction incidence during national lockdown in two French provinces unevenly affected by COVID-19 outbreak: An observational study
- Eric Van Belle,
- Thibault Manigold,
- Adeline Piérache,
- Alain Furber,
- Nicolas Debry,
- Anne Luycx-Bore,
- Jean-Jacques Bauchart,
- Olivier Nugue,
- François Huchet,
- Mathieu Bic,
- François Vinchon,
- Smaïn Sayah,
- Alexandre Fournier,
- Eric Decoulx,
- Usman Mouhammad,
- Jérôme Clerc,
- Aurélie Manchuelle,
- Tahar Lazizi,
- Akram Chmait,
- Julien Jeannetteau,
- Pierre Hénon,
- Mickael Bonin,
- Marie Dupret-Minet,
- Ashok Tirouvanziam,
- David Molcard,
- Fabien Arabucki,
- Antoine Py,
- Fabrice Prunier,
- Cédric Delhaye,
- Gilles Lemesle,
- Guillaume Schurtz,
- Alessandro Cosenza,
- Hugues Spillemaeker,
- Basile Verdier,
- Tom Denimal,
- Thibault Pamart,
- Habib Sylla,
- Dany Janah,
- David Aouate,
- Sina Porouchani,
- Valérie Guillez,
- Guillaume Bonnet,
- Julien Ternacle,
- Julien Labreuche,
- Guillaume Cayla,
- Flavien Vincent
Affiliations
- Eric Van Belle
- CHU Lille, Institut Cœur Poumon, Cardiology, Department of Interventional Cardiology for Coronary, Valves and Structural Heart Diseases, Inserm, U1011, Institut Pasteur de Lille, EGID, Université de Lille, Lille 59037, France; Corresponding author.
- Thibault Manigold
- CHU Nantes, Nantes, France
- Adeline Piérache
- Département de Biostatistiques, Univ. Lille, CHU Lille, ULR 2694 – METRICS: évaluation des technologies de santé et des pratiques médicales, F-59000 Lille, France
- Alain Furber
- Cardiologie, CHU Angers, France
- Nicolas Debry
- CH Saint-Philibert, Lille, France
- Anne Luycx-Bore
- CH Beauvais, Beauvais, France
- Jean-Jacques Bauchart
- Clinique la Louvière, Lille, France
- Olivier Nugue
- Centre hospitalier Boulogne, France
- François Huchet
- CH Saint-Nazaire, France
- Mathieu Bic
- CH Lens, France
- François Vinchon
- CH Le Mans, France
- Smaïn Sayah
- CH Creil, France
- Alexandre Fournier
- CHU Amiens, France
- Eric Decoulx
- CH Roubaix, France
- Usman Mouhammad
- CH Valenciennes, France
- Jérôme Clerc
- CH Compiègne, France
- Aurélie Manchuelle
- Clinique Bois Bernard, France
- Tahar Lazizi
- CH Laval, France
- Akram Chmait
- Clinique Côte d'Opale, Saint-Martin Boulogne, France
- Julien Jeannetteau
- Clinique Saint-Joseph, Angers, France
- Pierre Hénon
- CH Saint-Quentin, France, France
- Mickael Bonin
- CHU Nantes, Nantes, France
- Marie Dupret-Minet
- CH Dunkerque, France, France
- Ashok Tirouvanziam
- Polyclinique du Confluent, Nantes, France
- David Molcard
- CH Soissons, France
- Fabien Arabucki
- CH La Roche Sur Yon, France
- Antoine Py
- Clinique Victor Pauchet, Amiens, France
- Fabrice Prunier
- Cardiologie, CHU Angers, France
- Cédric Delhaye
- CHU Lille, Institut Cœur Poumon, Cardiology, Department of Interventional Cardiology for Coronary, Valves and Structural Heart Diseases, Inserm, U1011, Institut Pasteur de Lille, EGID, Université de Lille, Lille 59037, France
- Gilles Lemesle
- CHU Lille, Institut Cœur Poumon, Cardiology, Department of Interventional Cardiology for Coronary, Valves and Structural Heart Diseases, Inserm, U1011, Institut Pasteur de Lille, EGID, Université de Lille, Lille 59037, France
- Guillaume Schurtz
- CHU Lille, Institut Cœur Poumon, Cardiology, Department of Interventional Cardiology for Coronary, Valves and Structural Heart Diseases, Inserm, U1011, Institut Pasteur de Lille, EGID, Université de Lille, Lille 59037, France
- Alessandro Cosenza
- CHU Lille, Institut Cœur Poumon, Cardiology, Department of Interventional Cardiology for Coronary, Valves and Structural Heart Diseases, Inserm, U1011, Institut Pasteur de Lille, EGID, Université de Lille, Lille 59037, France
- Hugues Spillemaeker
- CHU Lille, Institut Cœur Poumon, Cardiology, Department of Interventional Cardiology for Coronary, Valves and Structural Heart Diseases, Inserm, U1011, Institut Pasteur de Lille, EGID, Université de Lille, Lille 59037, France
- Basile Verdier
- CHU Lille, Institut Cœur Poumon, Cardiology, Department of Interventional Cardiology for Coronary, Valves and Structural Heart Diseases, Inserm, U1011, Institut Pasteur de Lille, EGID, Université de Lille, Lille 59037, France
- Tom Denimal
- CHU Lille, Institut Cœur Poumon, Cardiology, Department of Interventional Cardiology for Coronary, Valves and Structural Heart Diseases, Inserm, U1011, Institut Pasteur de Lille, EGID, Université de Lille, Lille 59037, France
- Thibault Pamart
- CHU Lille, Institut Cœur Poumon, Cardiology, Department of Interventional Cardiology for Coronary, Valves and Structural Heart Diseases, Inserm, U1011, Institut Pasteur de Lille, EGID, Université de Lille, Lille 59037, France
- Habib Sylla
- CHU Lille, Institut Cœur Poumon, Cardiology, Department of Interventional Cardiology for Coronary, Valves and Structural Heart Diseases, Inserm, U1011, Institut Pasteur de Lille, EGID, Université de Lille, Lille 59037, France
- Dany Janah
- CHU Lille, Institut Cœur Poumon, Cardiology, Department of Interventional Cardiology for Coronary, Valves and Structural Heart Diseases, Inserm, U1011, Institut Pasteur de Lille, EGID, Université de Lille, Lille 59037, France
- David Aouate
- CHU Lille, Institut Cœur Poumon, Cardiology, Department of Interventional Cardiology for Coronary, Valves and Structural Heart Diseases, Inserm, U1011, Institut Pasteur de Lille, EGID, Université de Lille, Lille 59037, France
- Sina Porouchani
- CHU Lille, Institut Cœur Poumon, Cardiology, Department of Interventional Cardiology for Coronary, Valves and Structural Heart Diseases, Inserm, U1011, Institut Pasteur de Lille, EGID, Université de Lille, Lille 59037, France
- Valérie Guillez
- CHU Lille, Institut Cœur Poumon, Cardiology, Department of Interventional Cardiology for Coronary, Valves and Structural Heart Diseases, Inserm, U1011, Institut Pasteur de Lille, EGID, Université de Lille, Lille 59037, France
- Guillaume Bonnet
- Hôpital Cardiologique Haut-Lévêque, CHU de Bordeaux, 33600 Pessac, France
- Julien Ternacle
- Hôpital Cardiologique Haut-Lévêque, CHU de Bordeaux, 33600 Pessac, France
- Julien Labreuche
- Département de Biostatistiques, Univ. Lille, CHU Lille, ULR 2694 – METRICS: évaluation des technologies de santé et des pratiques médicales, F-59000 Lille, France
- Guillaume Cayla
- CHU Nîmes, France
- Flavien Vincent
- CHU Lille, Institut Cœur Poumon, Cardiology, Department of Interventional Cardiology for Coronary, Valves and Structural Heart Diseases, Inserm, U1011, Institut Pasteur de Lille, EGID, Université de Lille, Lille 59037, France; Corresponding author.
- Journal volume & issue
-
Vol. 2
p. 100030
Abstract
Background: A reduction of admission for MI has been reported in most countries affected by COVID-19. No clear explanation has been provided. Methods: To report the incidence of myocardial infarction (MI) admission during COVID-19 pandemic and in particular during national lockdown in two unequally affected French provinces (10-million inhabitants) with a different media strategy, and to describe the magnitude of MI incidence changes relative to the incidence of COVID-19-related deaths. A longitudinal study to collect all MIs from January 1 until May 17, 2020 (study period) and from the identical time period in 2019 (control period) was conducted in all centers with PCI-facilities in northern “Hauts-de-France” province and western “Pays-de-la-Loire” Province. The incidence of COVID-19 fatalities was also collected. Findings: In “Hauts-de-France”, during lockdown (March 18–May 10), 1500 COVID-19-related deaths were observed. A 23% decrease in MI-IR (IRR=0.77;95%CI:0.71–0.84, p<0.001) was observed for a loss of 272 MIs (95%CI:−363,−181), representing 18% of COVID-19-related deaths. In “Pays-de-la-Loire”, 382 COVID-19-related deaths were observed. A 19% decrease in MI-IR (IRR=0.81; 95%CI=0.73–0.90, p<0.001) was observed for a loss of 138 MIs (95%CI:−210,−66), representing 36% of COVID-19-related deaths. While in “Hauts-de-France” the MI decline started before lockdown and recovered 3 weeks before its end, in “Pays-de-la-Loire”, it started after lockdown and recovered only by its end. In-hospital mortality of MI patients was increased during lockdown in both provinces (5.0% vs 3.4%, p=0.02). Interpretation: It highlights one of the potential collateral damages of COVID-19 outbreak on cardiovascular health with a dramatic reduction of MI incidence. It advocates for a careful and weighted communication strategy in pandemic crises. Funding: The study was conducted without external funding.